Global Neuroblastoma Treatment Market 2022 by Company, Regions, Type and Application, Forecast to 2028

  • receipt Report ID : 119676
  • calendar_today Published On: Mar, 2022
  • file_copy Pages: 156
  • list Pharmaceuticals and Healthcare
Buy @ $3500

The Neuroblastoma Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

According to our latest study, due to COVID-19 pandemic, the global Neuroblastoma Treatment market size is estimated to be worth US$ 456.9 million in 2021 and is forecast to a readjusted size of USD 575.4 million by 2028 with a CAGR of 3.3% during review period. Hospitals accounting for % of the Neuroblastoma Treatment global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Combination Chemotherapy segment is altered to a % CAGR between 2022 and 2028.

Global key companies of Neuroblastoma Treatment include Seattle Children’s, CureSearch, Texas Children’s, NANT, and Sino Biopharmaceutical, etc. In terms of revenue, the global top four players hold a share over % in 2021.

Market segmentation

Neuroblastoma Treatment market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type, covers

Combination Chemotherapy

Monoclonal Antibody Therapy

Vaccine Therapy

Chimeric Antigen Receptor T-Cell Immunotherapy

Oncolytic Virus Therapy

Market segment by Application, can be divided into

Hospitals

Clinics

Others

Market segment by players, this report covers

Seattle Children’s

CureSearch

Texas Children’s

NANT

Sino Biopharmaceutical

Jiangsu Hengrui Medicine Co.,Ltd.

Fosun Pharmaceutical

Novartis

Juno Therapeutics

Kite Pharma

Adaptimmune

Market segment by regions, regional analysis covers

North America (United States, Canada, and Mexico)

Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)

South America (Brazil, Argentina, Rest of South America)

Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 12 chapters:

Chapter 1, to describe Neuroblastoma Treatment product scope, market overview, market opportunities, market driving force and market risks.

Chapter 2, to profile the top players of Neuroblastoma Treatment, with revenue, gross margin and global market share of Neuroblastoma Treatment from 2019 to 2022.

Chapter 3, the Neuroblastoma Treatment competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.

Chapter 4 and 5, to segment the market size by Type and application, with revenue and growth rate by Type, application, from 2017 to 2028.

Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2017 to 2022.and Neuroblastoma Treatment market forecast, by regions, type and application, with revenue, from 2023 to 2028.

Chapter 11 and 12, to describe Neuroblastoma Treatment research findings and conclusion, appendix and data source.

Frequently Asked Questions

The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.

Market is segmented on the basis:

  • By Type
  • By Application
  • By Region
  • By Country
  • By Manufacturer

The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.

The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.

1 Market Overview

1.1 Product Overview and Scope of Neuroblastoma Treatment

1.2 Classification of Neuroblastoma Treatment by Type

1.2.1 Overview: Global Neuroblastoma Treatment Market Size by Type: 2017 Versus 2021 Versus 2028

1.2.2 Global Neuroblastoma Treatment Revenue Market Share by Type in 2021

1.2.3 Combination Chemotherapy

1.2.4 Monoclonal Antibody Therapy

1.2.5 Vaccine Therapy

1.2.6 Chimeric Antigen Receptor T-Cell Immunotherapy

1.2.7 Oncolytic Virus Therapy

1.3 Global Neuroblastoma Treatment Market by Application

1.3.1 Overview: Global Neuroblastoma Treatment Market Size by Application: 2017 Versus 2021 Versus 2028

1.3.2 Hospitals

1.3.3 Clinics

1.3.4 Others

1.4 Global Neuroblastoma Treatment Market Size & Forecast

1.5 Global Neuroblastoma Treatment Market Size and Forecast by Region

1.5.1 Global Neuroblastoma Treatment Market Size by Region: 2017 VS 2021 VS 2028

1.5.2 Global Neuroblastoma Treatment Market Size by Region, (2017-2022)

1.5.3 North America Neuroblastoma Treatment Market Size and Prospect (2017-2028)

1.5.4 Europe Neuroblastoma Treatment Market Size and Prospect (2017-2028)

1.5.5 Asia-Pacific Neuroblastoma Treatment Market Size and Prospect (2017-2028)

1.5.6 South America Neuroblastoma Treatment Market Size and Prospect (2017-2028)

1.5.7 Middle East and Africa Neuroblastoma Treatment Market Size and Prospect (2017-2028)

1.6 Market Drivers, Restraints and Trends

1.6.1 Neuroblastoma Treatment Market Drivers

1.6.2 Neuroblastoma Treatment Market Restraints

1.6.3 Neuroblastoma Treatment Trends Analysis

2 Company Profiles

2.1 Seattle Children’s

2.1.1 Seattle Children’s Details

2.1.2 Seattle Children’s Major Business

2.1.3 Seattle Children’s Neuroblastoma Treatment Product and Solutions

2.1.4 Seattle Children’s Neuroblastoma Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.1.5 Seattle Children’s Recent Developments and Future Plans

2.2 CureSearch

2.2.1 CureSearch Details

2.2.2 CureSearch Major Business

2.2.3 CureSearch Neuroblastoma Treatment Product and Solutions

2.2.4 CureSearch Neuroblastoma Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.2.5 CureSearch Recent Developments and Future Plans

2.3 Texas Children’s

2.3.1 Texas Children’s Details

2.3.2 Texas Children’s Major Business

2.3.3 Texas Children’s Neuroblastoma Treatment Product and Solutions

2.3.4 Texas Children’s Neuroblastoma Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.3.5 Texas Children’s Recent Developments and Future Plans

2.4 NANT

2.4.1 NANT Details

2.4.2 NANT Major Business

2.4.3 NANT Neuroblastoma Treatment Product and Solutions

2.4.4 NANT Neuroblastoma Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.4.5 NANT Recent Developments and Future Plans

2.5 Sino Biopharmaceutical

2.5.1 Sino Biopharmaceutical Details

2.5.2 Sino Biopharmaceutical Major Business

2.5.3 Sino Biopharmaceutical Neuroblastoma Treatment Product and Solutions

2.5.4 Sino Biopharmaceutical Neuroblastoma Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.5.5 Sino Biopharmaceutical Recent Developments and Future Plans

2.6 Jiangsu Hengrui Medicine Co.,Ltd.

2.6.1 Jiangsu Hengrui Medicine Co.,Ltd. Details

2.6.2 Jiangsu Hengrui Medicine Co.,Ltd. Major Business

2.6.3 Jiangsu Hengrui Medicine Co.,Ltd. Neuroblastoma Treatment Product and Solutions

2.6.4 Jiangsu Hengrui Medicine Co.,Ltd. Neuroblastoma Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.6.5 Jiangsu Hengrui Medicine Co.,Ltd. Recent Developments and Future Plans

2.7 Fosun Pharmaceutical

2.7.1 Fosun Pharmaceutical Details

2.7.2 Fosun Pharmaceutical Major Business

2.7.3 Fosun Pharmaceutical Neuroblastoma Treatment Product and Solutions

2.7.4 Fosun Pharmaceutical Neuroblastoma Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.7.5 Fosun Pharmaceutical Recent Developments and Future Plans

2.8 Novartis

2.8.1 Novartis Details

2.8.2 Novartis Major Business

2.8.3 Novartis Neuroblastoma Treatment Product and Solutions

2.8.4 Novartis Neuroblastoma Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.8.5 Novartis Recent Developments and Future Plans

2.9 Juno Therapeutics

2.9.1 Juno Therapeutics Details

2.9.2 Juno Therapeutics Major Business

2.9.3 Juno Therapeutics Neuroblastoma Treatment Product and Solutions

2.9.4 Juno Therapeutics Neuroblastoma Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.9.5 Juno Therapeutics Recent Developments and Future Plans

2.10 Kite Pharma

2.10.1 Kite Pharma Details

2.10.2 Kite Pharma Major Business

2.10.3 Kite Pharma Neuroblastoma Treatment Product and Solutions

2.10.4 Kite Pharma Neuroblastoma Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.10.5 Kite Pharma Recent Developments and Future Plans

2.11 Adaptimmune

2.11.1 Adaptimmune Details

2.11.2 Adaptimmune Major Business

2.11.3 Adaptimmune Neuroblastoma Treatment Product and Solutions

2.11.4 Adaptimmune Neuroblastoma Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.11.5 Adaptimmune Recent Developments and Future Plans

3 Market Competition, by Players

3.1 Global Neuroblastoma Treatment Revenue and Share by Players (2019, 2020, 2021, and 2022)

3.2 Market Concentration Rate

3.2.1 Top 3 Neuroblastoma Treatment Players Market Share in 2021

3.2.2 Top 10 Neuroblastoma Treatment Players Market Share in 2021

3.2.3 Market Competition Trend

3.3 Neuroblastoma Treatment Players Head Office, Products and Services Provided

3.4 Neuroblastoma Treatment Mergers & Acquisitions

3.5 Neuroblastoma Treatment New Entrants and Expansion Plans

4 Market Size Segment by Type

4.1 Global Neuroblastoma Treatment Revenue and Market Share by Type (2017-2022)

4.2 Global Neuroblastoma Treatment Market Forecast by Type (2023-2028)

5 Market Size Segment by Application

5.1 Global Neuroblastoma Treatment Revenue Market Share by Application (2017-2022)

5.2 Global Neuroblastoma Treatment Market Forecast by Application (2023-2028)

6 North America by Country, by Type, and by Application

6.1 North America Neuroblastoma Treatment Revenue by Type (2017-2028)

6.2 North America Neuroblastoma Treatment Revenue by Application (2017-2028)

6.3 North America Neuroblastoma Treatment Market Size by Country

6.3.1 North America Neuroblastoma Treatment Revenue by Country (2017-2028)

6.3.2 United States Neuroblastoma Treatment Market Size and Forecast (2017-2028)

6.3.3 Canada Neuroblastoma Treatment Market Size and Forecast (2017-2028)

6.3.4 Mexico Neuroblastoma Treatment Market Size and Forecast (2017-2028)

7 Europe by Country, by Type, and by Application

7.1 Europe Neuroblastoma Treatment Revenue by Type (2017-2028)

7.2 Europe Neuroblastoma Treatment Revenue by Application (2017-2028)

7.3 Europe Neuroblastoma Treatment Market Size by Country

7.3.1 Europe Neuroblastoma Treatment Revenue by Country (2017-2028)

7.3.2 Germany Neuroblastoma Treatment Market Size and Forecast (2017-2028)

7.3.3 France Neuroblastoma Treatment Market Size and Forecast (2017-2028)

7.3.4 United Kingdom Neuroblastoma Treatment Market Size and Forecast (2017-2028)

7.3.5 Russia Neuroblastoma Treatment Market Size and Forecast (2017-2028)

7.3.6 Italy Neuroblastoma Treatment Market Size and Forecast (2017-2028)

8 Asia-Pacific by Region, by Type, and by Application

8.1 Asia-Pacific Neuroblastoma Treatment Revenue by Type (2017-2028)

8.2 Asia-Pacific Neuroblastoma Treatment Revenue by Application (2017-2028)

8.3 Asia-Pacific Neuroblastoma Treatment Market Size by Region

8.3.1 Asia-Pacific Neuroblastoma Treatment Revenue by Region (2017-2028)

8.3.2 China Neuroblastoma Treatment Market Size and Forecast (2017-2028)

8.3.3 Japan Neuroblastoma Treatment Market Size and Forecast (2017-2028)

8.3.4 South Korea Neuroblastoma Treatment Market Size and Forecast (2017-2028)

8.3.5 India Neuroblastoma Treatment Market Size and Forecast (2017-2028)

8.3.6 Southeast Asia Neuroblastoma Treatment Market Size and Forecast (2017-2028)

8.3.7 Australia Neuroblastoma Treatment Market Size and Forecast (2017-2028)

9 South America by Country, by Type, and by Application

9.1 South America Neuroblastoma Treatment Revenue by Type (2017-2028)

9.2 South America Neuroblastoma Treatment Revenue by Application (2017-2028)

9.3 South America Neuroblastoma Treatment Market Size by Country

9.3.1 South America Neuroblastoma Treatment Revenue by Country (2017-2028)

9.3.2 Brazil Neuroblastoma Treatment Market Size and Forecast (2017-2028)

9.3.3 Argentina Neuroblastoma Treatment Market Size and Forecast (2017-2028)

10 Middle East & Africa by Country, by Type, and by Application

10.1 Middle East & Africa Neuroblastoma Treatment Revenue by Type (2017-2028)

10.2 Middle East & Africa Neuroblastoma Treatment Revenue by Application (2017-2028)

10.3 Middle East & Africa Neuroblastoma Treatment Market Size by Country

10.3.1 Middle East & Africa Neuroblastoma Treatment Revenue by Country (2017-2028)

10.3.2 Turkey Neuroblastoma Treatment Market Size and Forecast (2017-2028)

10.3.3 Saudi Arabia Neuroblastoma Treatment Market Size and Forecast (2017-2028)

10.3.4 UAE Neuroblastoma Treatment Market Size and Forecast (2017-2028)

11 Research Findings and Conclusion

12 Appendix

12.1 Methodology

12.2 Research Process and Data Source

12.3 Disclaimer

List of Tables

Table 1. Global Neuroblastoma Treatment Revenue by Type, (USD Million), 2017 VS 2021 VS 2028

Table 2. Global Neuroblastoma Treatment Revenue by Application, (USD Million), 2017 VS 2021 VS 2028

Table 3. Global Market Neuroblastoma Treatment Revenue (Million USD) Comparison by Region (2017 VS 2021 VS 2028)

Table 4. Global Neuroblastoma Treatment Revenue (USD Million) by Region (2017-2022)

Table 5. Global Neuroblastoma Treatment Revenue Market Share by Region (2023-2028)

Table 6. Seattle Children’s Corporate Information, Head Office, and Major Competitors

Table 7. Seattle Children’s Major Business

Table 8. Seattle Children’s Neuroblastoma Treatment Product and Solutions

Table 9. Seattle Children’s Neuroblastoma Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 10. CureSearch Corporate Information, Head Office, and Major Competitors

Table 11. CureSearch Major Business

Table 12. CureSearch Neuroblastoma Treatment Product and Solutions

Table 13. CureSearch Neuroblastoma Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 14. Texas Children’s Corporate Information, Head Office, and Major Competitors

Table 15. Texas Children’s Major Business

Table 16. Texas Children’s Neuroblastoma Treatment Product and Solutions

Table 17. Texas Children’s Neuroblastoma Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 18. NANT Corporate Information, Head Office, and Major Competitors

Table 19. NANT Major Business

Table 20. NANT Neuroblastoma Treatment Product and Solutions

Table 21. NANT Neuroblastoma Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 22. Sino Biopharmaceutical Corporate Information, Head Office, and Major Competitors

Table 23. Sino Biopharmaceutical Major Business

Table 24. Sino Biopharmaceutical Neuroblastoma Treatment Product and Solutions

Table 25. Sino Biopharmaceutical Neuroblastoma Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 26. Jiangsu Hengrui Medicine Co.,Ltd. Corporate Information, Head Office, and Major Competitors

Table 27. Jiangsu Hengrui Medicine Co.,Ltd. Major Business

Table 28. Jiangsu Hengrui Medicine Co.,Ltd. Neuroblastoma Treatment Product and Solutions

Table 29. Jiangsu Hengrui Medicine Co.,Ltd. Neuroblastoma Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 30. Fosun Pharmaceutical Corporate Information, Head Office, and Major Competitors

Table 31. Fosun Pharmaceutical Major Business

Table 32. Fosun Pharmaceutical Neuroblastoma Treatment Product and Solutions

Table 33. Fosun Pharmaceutical Neuroblastoma Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 34. Novartis Corporate Information, Head Office, and Major Competitors

Table 35. Novartis Major Business

Table 36. Novartis Neuroblastoma Treatment Product and Solutions

Table 37. Novartis Neuroblastoma Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 38. Juno Therapeutics Corporate Information, Head Office, and Major Competitors

Table 39. Juno Therapeutics Major Business

Table 40. Juno Therapeutics Neuroblastoma Treatment Product and Solutions

Table 41. Juno Therapeutics Neuroblastoma Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 42. Kite Pharma Corporate Information, Head Office, and Major Competitors

Table 43. Kite Pharma Major Business

Table 44. Kite Pharma Neuroblastoma Treatment Product and Solutions

Table 45. Kite Pharma Neuroblastoma Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 46. Adaptimmune Corporate Information, Head Office, and Major Competitors

Table 47. Adaptimmune Major Business

Table 48. Adaptimmune Neuroblastoma Treatment Product and Solutions

Table 49. Adaptimmune Neuroblastoma Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 50. Global Neuroblastoma Treatment Revenue (USD Million) by Players (2019, 2020, 2021, and 2022)

Table 51. Global Neuroblastoma Treatment Revenue Share by Players (2019, 2020, 2021, and 2022)

Table 52. Breakdown of Neuroblastoma Treatment by Company Type (Tier 1, Tier 2 and Tier 3)

Table 53. Neuroblastoma Treatment Players Head Office, Products and Services Provided

Table 54. Neuroblastoma Treatment Mergers & Acquisitions in the Past Five Years

Table 55. Neuroblastoma Treatment New Entrants and Expansion Plans

Table 56. Global Neuroblastoma Treatment Revenue (USD Million) by Type (2017-2022)

Table 57. Global Neuroblastoma Treatment Revenue Share by Type (2017-2022)

Table 58. Global Neuroblastoma Treatment Revenue Forecast by Type (2023-2028)

Table 59. Global Neuroblastoma Treatment Revenue by Application (2017-2022)

Table 60. Global Neuroblastoma Treatment Revenue Forecast by Application (2023-2028)

Table 61. North America Neuroblastoma Treatment Revenue by Type (2017-2022) & (USD Million)

Table 62. North America Neuroblastoma Treatment Revenue by Type (2023-2028) & (USD Million)

Table 63. North America Neuroblastoma Treatment Revenue by Application (2017-2022) & (USD Million)

Table 64. North America Neuroblastoma Treatment Revenue by Application (2023-2028) & (USD Million)

Table 65. North America Neuroblastoma Treatment Revenue by Country (2017-2022) & (USD Million)

Table 66. North America Neuroblastoma Treatment Revenue by Country (2023-2028) & (USD Million)

Table 67. Europe Neuroblastoma Treatment Revenue by Type (2017-2022) & (USD Million)

Table 68. Europe Neuroblastoma Treatment Revenue by Type (2023-2028) & (USD Million)

Table 69. Europe Neuroblastoma Treatment Revenue by Application (2017-2022) & (USD Million)

Table 70. Europe Neuroblastoma Treatment Revenue by Application (2023-2028) & (USD Million)

Table 71. Europe Neuroblastoma Treatment Revenue by Country (2017-2022) & (USD Million)

Table 72. Europe Neuroblastoma Treatment Revenue by Country (2023-2028) & (USD Million)

Table 73. Asia-Pacific Neuroblastoma Treatment Revenue by Type (2017-2022) & (USD Million)

Table 74. Asia-Pacific Neuroblastoma Treatment Revenue by Type (2023-2028) & (USD Million)

Table 75. Asia-Pacific Neuroblastoma Treatment Revenue by Application (2017-2022) & (USD Million)

Table 76. Asia-Pacific Neuroblastoma Treatment Revenue by Application (2023-2028) & (USD Million)

Table 77. Asia-Pacific Neuroblastoma Treatment Revenue by Region (2017-2022) & (USD Million)

Table 78. Asia-Pacific Neuroblastoma Treatment Revenue by Region (2023-2028) & (USD Million)

Table 79. South America Neuroblastoma Treatment Revenue by Type (2017-2022) & (USD Million)

Table 80. South America Neuroblastoma Treatment Revenue by Type (2023-2028) & (USD Million)

Table 81. South America Neuroblastoma Treatment Revenue by Application (2017-2022) & (USD Million)

Table 82. South America Neuroblastoma Treatment Revenue by Application (2023-2028) & (USD Million)

Table 83. South America Neuroblastoma Treatment Revenue by Country (2017-2022) & (USD Million)

Table 84. South America Neuroblastoma Treatment Revenue by Country (2023-2028) & (USD Million)

Table 85. Middle East & Africa Neuroblastoma Treatment Revenue by Type (2017-2022) & (USD Million)

Table 86. Middle East & Africa Neuroblastoma Treatment Revenue by Type (2023-2028) & (USD Million)

Table 87. Middle East & Africa Neuroblastoma Treatment Revenue by Application (2017-2022) & (USD Million)

Table 88. Middle East & Africa Neuroblastoma Treatment Revenue by Application (2023-2028) & (USD Million)

Table 89. Middle East & Africa Neuroblastoma Treatment Revenue by Country (2017-2022) & (USD Million)

Table 90. Middle East & Africa Neuroblastoma Treatment Revenue by Country (2023-2028) & (USD Million)

List of Figures

Figure 1. Neuroblastoma Treatment Picture

Figure 2. Global Neuroblastoma Treatment Revenue Market Share by Type in 2021

Figure 3. Combination Chemotherapy

Figure 4. Monoclonal Antibody Therapy

Figure 5. Vaccine Therapy

Figure 6. Chimeric Antigen Receptor T-Cell Immunotherapy

Figure 7. Oncolytic Virus Therapy

Figure 8. Neuroblastoma Treatment Revenue Market Share by Application in 2021

Figure 9. Hospitals Picture

Figure 10. Clinics Picture

Figure 11. Others Picture

Figure 12. Global Neuroblastoma Treatment Market Size, (USD Million): 2017 VS 2021 VS 2028

Figure 13. Global Neuroblastoma Treatment Revenue and Forecast (2017-2028) & (USD Million)

Figure 14. Global Neuroblastoma Treatment Revenue Market Share by Region (2017-2028)

Figure 15. Global Neuroblastoma Treatment Revenue Market Share by Region in 2021

Figure 16. North America Neuroblastoma Treatment Revenue (USD Million) and Growth Rate (2017-2028)

Figure 17. Europe Neuroblastoma Treatment Revenue (USD Million) and Growth Rate (2017-2028)

Figure 18. Asia-Pacific Neuroblastoma Treatment Revenue (USD Million) and Growth Rate (2017-2028)

Figure 19. South America Neuroblastoma Treatment Revenue (USD Million) and Growth Rate (2017-2028)

Figure 20. Middle East and Africa Neuroblastoma Treatment Revenue (USD Million) and Growth Rate (2017-2028)

Figure 21. Neuroblastoma Treatment Market Drivers

Figure 22. Neuroblastoma Treatment Market Restraints

Figure 23. Neuroblastoma Treatment Market Trends

Figure 24. Seattle Children’s Recent Developments and Future Plans

Figure 25. CureSearch Recent Developments and Future Plans

Figure 26. Texas Children’s Recent Developments and Future Plans

Figure 27. NANT Recent Developments and Future Plans

Figure 28. Sino Biopharmaceutical Recent Developments and Future Plans

Figure 29. Jiangsu Hengrui Medicine Co.,Ltd. Recent Developments and Future Plans

Figure 30. Fosun Pharmaceutical Recent Developments and Future Plans

Figure 31. Novartis Recent Developments and Future Plans

Figure 32. Juno Therapeutics Recent Developments and Future Plans

Figure 33. Kite Pharma Recent Developments and Future Plans

Figure 34. Adaptimmune Recent Developments and Future Plans

Figure 35. Global Neuroblastoma Treatment Revenue Share by Players in 2021

Figure 36. Neuroblastoma Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2021

Figure 37. Global Top 3 Players Neuroblastoma Treatment Revenue Market Share in 2021

Figure 38. Global Top 10 Players Neuroblastoma Treatment Revenue Market Share in 2021

Figure 39. Key Players Market Share Trend (Top 3 Market Share: 2020 VS 2021 VS 2022)

Figure 40. Global Neuroblastoma Treatment Revenue Share by Type in 2021

Figure 41. Global Neuroblastoma Treatment Market Share Forecast by Type (2023-2028)

Figure 42. Global Neuroblastoma Treatment Revenue Share by Application in 2021

Figure 43. Global Neuroblastoma Treatment Market Share Forecast by Application (2023-2028)

Figure 44. North America Neuroblastoma Treatment Sales Market Share by Type (2017-2028)

Figure 45. North America Neuroblastoma Treatment Sales Market Share by Application (2017-2028)

Figure 46. North America Neuroblastoma Treatment Revenue Market Share by Country (2017-2028)

Figure 47. United States Neuroblastoma Treatment Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 48. Canada Neuroblastoma Treatment Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 49. Mexico Neuroblastoma Treatment Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 50. Europe Neuroblastoma Treatment Sales Market Share by Type (2017-2028)

Figure 51. Europe Neuroblastoma Treatment Sales Market Share by Application (2017-2028)

Figure 52. Europe Neuroblastoma Treatment Revenue Market Share by Country (2017-2028)

Figure 53. Germany Neuroblastoma Treatment Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 54. France Neuroblastoma Treatment Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 55. United Kingdom Neuroblastoma Treatment Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 56. Russia Neuroblastoma Treatment Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 57. Italy Neuroblastoma Treatment Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 58. Asia-Pacific Neuroblastoma Treatment Sales Market Share by Type (2017-2028)

Figure 59. Asia-Pacific Neuroblastoma Treatment Sales Market Share by Application (2017-2028)

Figure 60. Asia-Pacific Neuroblastoma Treatment Revenue Market Share by Region (2017-2028)

Figure 61. China Neuroblastoma Treatment Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 62. Japan Neuroblastoma Treatment Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 63. South Korea Neuroblastoma Treatment Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 64. India Neuroblastoma Treatment Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 65. Southeast Asia Neuroblastoma Treatment Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 66. Australia Neuroblastoma Treatment Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 67. South America Neuroblastoma Treatment Sales Market Share by Type (2017-2028)

Figure 68. South America Neuroblastoma Treatment Sales Market Share by Application (2017-2028)

Figure 69. South America Neuroblastoma Treatment Revenue Market Share by Country (2017-2028)

Figure 70. Brazil Neuroblastoma Treatment Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 71. Argentina Neuroblastoma Treatment Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 72. Middle East and Africa Neuroblastoma Treatment Sales Market Share by Type (2017-2028)

Figure 73. Middle East and Africa Neuroblastoma Treatment Sales Market Share by Application (2017-2028)

Figure 74. Middle East and Africa Neuroblastoma Treatment Revenue Market Share by Country (2017-2028)

Figure 75. Turkey Neuroblastoma Treatment Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 76. Saudi Arabia Neuroblastoma Treatment Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 77. UAE Neuroblastoma Treatment Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 78. Methodology

Figure 79. Research Process and Data Source

shopping_cart License Type

Buy Now

email Quick Contact

+1

tag_faces Our Clients

help Need Help?

Please contact directly on our US and India numbers

+1-201-465-4211

Please feel free to write an email to us or to use our electronic ticketing system.

sales@marketquest.biz